Those with ongoing fatigue, neurological symptoms, or high stress may require more frequent intervals
U S A 107, 75567561
Ernie Blevins, an endocrinologist at the University of Washington, and his colleagues co-administered oxytocin and a low dose of tirzepatide, a dual agonist mimicking the effects of both GLP-1 and glucose-dependent insulinotropic polypeptide, to obese rats and discovered that together, they produced more pronounced weight loss than either treatment alone
Those with a long half-life (weekly exenatide, efpeglenatide, liraglutide, semaglutide, albiglutide and dulaglutide) produce a sustained activation of rGLP1, resulting in a greater reduction in HbA1c, basal glycemia and body weight and would have fewer gastrointestinal side effects
GIP medications work by reducing hunger, and people then prefer to eat less throughout the day